Synthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moieties

Basit Öğe Kaydı
dc.authoridTekin, Suat/0000-0002-2757-1802
dc.authoridKUCUKBAY, HASAN/0000-0002-7180-9486;
dc.authorwosidTekin, Suat/KEI-2266-2024
dc.authorwosidTekin, Suat/AAG-1440-2021
dc.authorwosidTekin, Suat/IZD-9868-2023
dc.authorwosidKUCUKBAY, HASAN/A-5050-2019
dc.authorwosidYuksel, Furkan/KHD-2785-2024
dc.contributor.authorZebbiche, Zineddine
dc.contributor.authorTekin, Suat
dc.contributor.authorKucukbay, Hasan
dc.contributor.authorYuksel, Furkan
dc.contributor.authorBoumoud, Boudjemaa
dc.date.accessioned2024-08-04T20:49:10Z
dc.date.available2024-08-04T20:49:10Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractNine novel hydrazone derivatives (4a-i) incorporating pyridine and isatin moieties were synthesized through one-pot, four-component heterocyclic condensation reactions. The structures of all new compounds (2a-e, 3a, 3c-e, and 4a-e) were identified by H-1 nuclear magnetic resonance (NMR), C-13 NMR, and Fourier-transform infrared spectroscopic techniques and elemental analysis. Cell viability assays for the tested hydrazone derivatives were performed and the log IC50 values of the compounds were calculated after a 24-h treatment. All hydrazide derivatives tested showed a promising antitumor activity against A-2780 cells as compared with the standard drug docetaxel with a log IC50 value of 0.2200 mu M (p < .05). Seven of the examined compounds (4b-e, 4g-i) showed high cytotoxic activity against A-2780 cells as compared with the standard drug docetaxel. Whereas the log IC50 of docetaxel was 0.2200 mu M for A-2780 cells at 24 h, the IC50 values of these compounds were -0.4987, -0.4044, -0.8138, -0.3868, -0.6954, -0.4751, and 0.1809 mu M, respectively. Three of the compounds, 4b, 4d, and 4i, showed high cytotoxic activity against MCF-7 cells as compared with docetaxel (p < .05). Whereas the log IC50 of docetaxel was 0.2400 mu M for MCF-7 cells at 24 h, the log IC50 values of compounds 4b, 4d, and 4i were -0.1293, -0.1700, and 0.2459 mu M, respectively.en_US
dc.description.sponsorshipInonu University, Malatya Turkey; Mentouri Constantine University, Constantine, Algeriaen_US
dc.description.sponsorshipThe authors thank Inonu University, Malatya Turkey, and Mentouri Constantine University, Constantine, Algeria, for financial support.en_US
dc.identifier.doi10.1002/ardp.202000377
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue5en_US
dc.identifier.pmid33368627en_US
dc.identifier.scopus2-s2.0-85098159807en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1002/ardp.202000377
dc.identifier.urihttps://hdl.handle.net/11616/99689
dc.identifier.volume354en_US
dc.identifier.wosWOS:000602616600001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-V C H Verlag Gmbhen_US
dc.relation.ispartofArchiv Der Pharmazieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectanticancer activityen_US
dc.subjecthydrazone derivativesen_US
dc.subjectisatin derivativesen_US
dc.subjectpyridine derivativesen_US
dc.titleSynthesis and anticancer properties of novel hydrazone derivatives incorporating pyridine and isatin moietiesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu